Quantcast

Latest treatment of multiple sclerosis Stories

2009-08-31 11:28:57

Mitoxantrone: highly efficient escalation therapy in multiple sclerosisAccording to data supplied by the German Multiple Sclerosis Society's national MS register (DMSG - Deutsche Multiple Sklerose Gesellschaft), up to 10% of German MS patients have been treated with mitoxantrone in the past few years. Numerous studies have shown that it is highly efficient in suppressing disease activity. It is administered as so-called escalation therapy when other medication no longer suffices and in...

2009-08-25 10:49:00

CAMBRIDGE, Mass., Aug. 25 /PRNewswire/ -- Peptimmune, Inc., a privately held biotechnology company, announced the completion of a clinical trial to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of PI-2301 in subjects with Secondary Progressive Multiple Sclerosis (SP-MS). PI-2301 is a novel peptide copolymer for the treatment of multiple sclerosis and other autoimmune diseases. The Phase Ib multiple-ascending dose, double-blind, placebo-controlled, randomized...

2009-07-27 16:00:00

INDIANAPOLIS and EDMONTON, Alberta, July 27 /PRNewswire-FirstCall/ -- Eli Lilly and Company (NYSE: LLY) and BioMS Medical Corp. (TSX: MS) today announced that dirucotide did not meet the primary endpoint of delaying disease progression, as measured by the Expanded Disability Status Scale (EDSS), during the two-year MAESTRO-01 Phase III trial in patients with secondary progressive multiple sclerosis (SPMS). In addition, there were no statistically significant differences between dirucotide...

2009-07-17 16:00:00

Toronto Stock Exchange Symbol: MS EDMONTON, July 17 /PRNewswire-FirstCall/ - BioMS Medical Corp. (TSX: MS), a leading developer in the treatment of multiple sclerosis (MS), today announced financial and operational results for the three and six months ended June 30, 2009. "The pivotal phase III MAESTRO-01 trial has completed the last patient last visit, and we are expecting results from this study within the second half of this year. This is the first of our two pivotal trials evaluating...

2009-07-13 15:46:26

 Patients with multiple sclerosis who smoke appear to experience a more rapid progression of their disease, according to a report in the July issue of Archives of Neurology, one of the JAMA/Archives journals.Cigarette smokers are at higher risk of developing multiple sclerosis (MS), according to background information in the article. However, the effect of smoking on the progression of MS remains uncertain.Brian C. Healy, Ph.D., of Brigham and Women's Hospital, Harvard Medical School and...

2009-05-28 07:00:00

Toronto Stock Exchange Symbol: MS EDMONTON, May 28 /PRNewswire-FirstCall/ - BioMS Medical Corp (TSX: MS), a leading developer in the treatment of multiple sclerosis (MS), today announced that Mr. Randy Stroud, Vice President Regulatory Affairs, will present at the Canadian Society for Pharmaceutical Sciences 12th Annual Meeting & Symposium. TITLE: "Dirucotide: A Potential Therapy for Multiple Sclerosis" WHEN: Thursday June 4th at 2:00 pm (Eastern Time) WHERE:...

2009-05-11 16:30:00

Toronto Stock Exchange Symbol: MS EDMONTON, May 11 /PRNewswire-FirstCall/ - BioMS Medical Corp. (TSX: MS), a leading developer in the treatment of multiple sclerosis (MS), today announced financial and operational results for the first quarter, ended March 31, 2009. "We remain on track to obtain the results from MAESTRO-01, the first of our two pivotal trials evaluating dirucotide in patients with secondary progressive multiple sclerosis, in the second half of 2009," said Kevin Giese,...

2009-04-29 07:00:00

Toronto Stock Exchange Symbol: MS EDMONTON, April 29 /PRNewswire-FirstCall/ - BioMS Medical Corp (TSX: MS), a leading developer in the treatment of multiple sclerosis (MS), today announced that Mr. Kevin Giese, President and CEO, will present at a session entitled "Leveraging on energy wealth: the development of a world class technology sector" as part of the Alberta Economic Forum in Geneva in Switzerland. WHEN: Monday May 4th at 10:05am (Local time) WHERE: Grand Hotel...

2009-04-29 07:00:00

SEATTLE, April 29 /PRNewswire/ -- New analyses of data from the 16-Year Long-term Follow-up study with Betaseron(R) (interferon beta-1b), sponsored by Bayer HealthCare Pharmaceuticals, were presented at the American Academy of Neurology's (AAN) 61st Annual Meeting. The study results showed that early and sustained exposure to Betaseron in study participants with multiple sclerosis (MS) were more likely to avoid a negative clinical outcome as demonstrated years later.(1) In this study, early...

2009-04-24 07:00:00

Toronto Stock Exchange Symbol: MS EDMONTON, April 24 /PRNewswire-FirstCall/ - BioMS Medical Corp (TSX: MS), a leading developer in the treatment of multiple sclerosis (MS), today announced that Mr. Tony Hesby, Executive Vice President, will present at BioFinance 2009 in Toronto. WHEN: Wednesday April 29th at 11:00am (Eastern Time) WHERE: Toronto Marriott Eaton Centre Hotel (Trinity V room) 525 Bay Street Toronto, ON About BioFinance 2009...


Word of the Day
omphalos
  • The navel or umbilicus.
  • In Greek archaeology: A central boss, as on a shield, a bowl, etc.
  • A sacred stone in the temple of Apollo at Delphi, believed by the Greeks to mark the 'navel' or exact center-point of the earth.
'Omphalos' comes from the ancient Greek.
Related